Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,484.80
(
-0.99%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
108.13
(
2.89%
)
Bitcoin
67,838.00
(
0.00%
)
News Focus
News Focus
Post# of 257269
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Bio_pete

Send PM Follow Ignore
Followers 17
Posts 1580
Boards Moderated 0
Alias Born 02/07/2007

Bio_pete

Re: zigzagman post# 91341

Saturday, 02/27/2010 4:30:28 PM

Saturday, February 27, 2010 4:30:28 PM

Post# of 257269
ANX- "Of course, a 30% injection site reaction by users of Vinorelbine might well fit that definition..wouldn't you think"

Even if you eliminate all reactions there's better drugs available. How can you get an unmet need designation for a second line drug. Its not the reaction thats the problem its the drugs efficacy.

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today